Rezolute, Inc. $RZLT Shares Purchased by OMERS ADMINISTRATION Corp

Key Points

• OMERS ADMINISTRATION Corp increased its stake in Rezolute, Inc. by 56.4% during the first quarter, now holding 118,900 shares valued at approximately $345,000.
• Analysts have a consensus rating of "Buy" for Rezolute, with target prices ranging from $12.00 to $14.00, despite one analyst downgrading the stock to a "sell" rating.
• Director Young-Jin Kim purchased 1,230,769 shares at an average price of $3.25 per share, increasing ownership by 17.11%, while insiders collectively bought over 1.2 million shares in the last 90 days.

OMERS ADMINISTRATION Corp grew its stake in Rezolute, Inc. (NASDAQ:RZLT - Free Report) by 56.4% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 118,900 shares of the company's stock after purchasing an additional 42,900 shares during the period. OMERS ADMINISTRATION Corp owned approximately 0.20% of Rezolute worth $345,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of the stock. Woodline Partners LP lifted its holdings in shares of Rezolute by 2,817.1% during the fourth quarter. Woodline Partners LP now owns 1,089,345 shares of the company's stock worth $5,338,000 after purchasing an additional 1,052,002 shares during the period. Integral Health Asset Management LLC raised its position in Rezolute by 100.0% during the 4th quarter. Integral Health Asset Management LLC now owns 500,000 shares of the company's stock worth $2,450,000 after buying an additional 250,000 shares during the last quarter. J. Goldman & Co LP purchased a new position in Rezolute during the 4th quarter worth $1,140,000. Point72 Europe London LLP purchased a new position in Rezolute during the 4th quarter worth $720,000. Finally, Dimensional Fund Advisors LP raised its position in Rezolute by 222.6% during the 4th quarter. Dimensional Fund Advisors LP now owns 185,768 shares of the company's stock worth $910,000 after buying an additional 128,190 shares during the last quarter. Hedge funds and other institutional investors own 82.97% of the company's stock.

Rezolute Trading Up 8.4%

RZLT traded up $0.62 on Friday, hitting $8.00. 1,560,305 shares of the company were exchanged, compared to its average volume of 738,004. The business's fifty day moving average is $6.03 and its 200 day moving average is $4.49. Rezolute, Inc. has a fifty-two week low of $2.21 and a fifty-two week high of $8.06.

Analysts Set New Price Targets

Several research firms recently issued reports on RZLT. HC Wainwright reissued a "buy" rating and set a $14.00 price target on shares of Rezolute in a report on Wednesday. Wall Street Zen cut Rezolute from a "hold" rating to a "sell" rating in a research report on Thursday, May 22nd. Finally, Wedbush reissued an "outperform" rating and issued a $12.00 price target on shares of Rezolute in a report on Wednesday, May 14th. One investment analyst has rated the stock with a Strong Buy rating and five have issued a Buy rating to the company's stock. According to MarketBeat.com, Rezolute has a consensus rating of "Buy" and a consensus price target of $12.50.

Insiders Place Their Bets

In related news, Director Young-Jin Kim bought 1,230,769 shares of the stock in a transaction on Friday, June 13th. The shares were bought at an average cost of $3.25 per share, for a total transaction of $3,999,999.25. Following the completion of the transaction, the director owned 8,423,386 shares of the company's stock, valued at $27,376,004.50. This represents a 17.11% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders have bought 1,241,345 shares of company stock worth $4,041,196 in the last quarter. Corporate insiders own 18.39% of the company's stock.

About Rezolute

Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.